Y-mAbs Therapeutics (YMAB) Misses Q2 EPS by 27c

Y-mAbs Therapeutics (NASDAQ: YMAB) reported Q2 EPS of ($0.94), $0.27 worse than the analyst estimate of ($0.67). Revenue for the quarter came in at $10.8 million versus the consensus estimate of $11.23 million.

For earnings history and earnings-related data on Y-mAbs Therapeutics (YMAB) click here.

You May Also Be Interested In

• Wolfe Research starts Ferrari at Outperform, sees 'solid upside potential'
• Core Molding Technologies extends credit facility to 2031
• Samsung 2q Oper Profit 89.40t Won, Est. 84.2t Won